Senra ALA, Andara RMT, Noa PG

Language: Spanish
References: 34
Page: 27-39
PDF size: 108.51 Kb.

ABSTRACT

Introduction: liver metastases represent an advanced stage of cancer; in some cases treatment achieves a survival benefit.
Objective: characterize patients with liver metastasis as the presenting symptom of cancer.
Methods: a descriptive, longitudinal, prospective study was conducted in 60 patients with liver metastases treated at Hermanos Ameijeiras Hospital from January 2010 to June, 2013. Variables were selected by calculating absolute numbers and percentages (%) as summary measures for qualitative variables, mean and standard deviation for quantitative variables. A significance level of 5 % was used and estimates variables were interpreted as corresponding.
Results: the mean age was 59 years; male patients were significantly more (65 %). As a main symptom/sign hepatomegaly (66.6 %) and abdominal pain (56.6 %) were highlighted. The physical condition of these patients at diagnosis was determined by the scale of Eastern Cooperative Oncology Group: 46.7 % had a performance status (PS) grade 0, followed by grade 3 (20 %). predominant histological type was adenocarcinoma (38.3 %). It was not possible to identify the primary tumor in 28.3 % of cases. The pancreas was the most common primary tumor site (15 %). The most frequent coincident metastases sites were lymph node (16.6 %) and lung (10 %).
Conclusions: liver metastases as forms in which this disease is presented was more common in men and older than 60 years of age. Hepatomegaly was the main clinical manifestation and the most usual histology was adenocarcinoma. It was not possible to identify the primary tumor in 28.3 % of cases and most frequently identified primary site was pancreas. Lymph nodes and lungs were the most commonly affected organs by coincident metastases.

REFERENCES

1. Muir C. Cancer of unknown primary site. Cancer. 2005;75:353.

2. Sleisenger and Fordtran's Gastrointestinal and Liver Disease Pathophysiology, Diagnosis and Management. 9 ed. Vol. 2. Madrid: Editorial Elsevier; 2010. p. 1583.

3. Washington K. Pathology of primary and secondary liver tumors. En: Clavien PA. Malignant liver tumors. Current and emerging therapies. Massachusetts, London: Blackwell Science; 1999. p. 137-49.

4. Beckingham I, Krige J. Liver tumors. BMJ. 2001;322:477-80.

5. Penna C. Prise en charge des patients ayant un cancer du foie. Les métastases hépatiques des cancers colo-rectaux. Bull Cancer. 2003;90:79-83.

6. Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin N Am. 2002;82:1075-90.

7. Bengtsson G, Carlsson G, Hafstrom L, Jonson P. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141:586-9.

8. Stangl R, Altendorf-Hofmann A, Charnley R, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405-10.

9. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999;5:3403-10.

10. Pavlidis N, Briasoulis E, Hainswoth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1900-2005.

11. Varadhachary GR, Greco A. Overview of management and future directions in unknown primary carcinoma. Sem Oncol. 2009;36(1):75-80.

12. Mc Gill DB. Liver Biopsy: When, How, by Whom, and Where? Current Gastroenterology. 2001;1:19-23.

13. Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR. The influence of comorbidities, age, and ps on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site. Cancer. 2006;106(9):2058-66.

14. Hogan BA, Thornton FJ, Brannigan M, Browne TJ, Pender S, O'Kelly P, et al. Hepatic metastases from an unknown primary neoplasm (UPN): survival, prognostic indicators and value of extensive investigations. Clin Radiol. 2002 Dec;57(12):1073-7.

15. Senra Armas L, Hernández Torres E, Álvarez Santana R, Rodríguez Silva H, Cand Huerta C, Roca Campañá V. Valor del examen post mortem en pacientes con cáncer de tumor primario oculto. Rev Cubana Med. 2011;50(4):376-89.

16. Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR. The Influence of Comorbidities, Age, and PS on the Prognosis and Treatment of Patients with Metastatic Carcinomas of Unknown Primary Site. Cancer. 2006;106(9):2058-66.

17. Ho Yi J, La Choi Y, Jin Lee S. Clinical presentation of carcinoma of unknown primary: 14 years of experience. Tumor Biol. 2011;32:45-51.

18. Pouessel D, Thezenas S, Culine S, Becht C, Senesse P, Ychou M. Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol. 2005 Dec; 29(12):1224-32.

19. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N. Liver metastases from cancer of unknown primary (CUP): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev. 2008;34(8):693-700.

20. Bugat R, Bataillard A, Lesimple T. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer. 2003;89(Suppl 1):S59-S66.

21. Culine S, Kramar A, Saghatchian M. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20:4679-83.

22. Nishimori H, Takahashi S, Katsuyuki K, Ennichi D, Kobashi T, Sano K, et al. Cancer of Unknown Primary Site:A Review of 28 Cases and the Efficacy of Cisplatin/Docetaxel Therapy at a Single Institute in Japan. Acta Med Okayama. 2010;64(5):285-91.

23. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G, on behalf of the ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi64-vi68.

24. Pouessel D, Thezenas S, Culine S, Becht C, Senesse P, Ychou M. Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol. 2005 Dec;29(12):1224-32.

25. Hogan BA, Thornton FJ, Brannigan M, Browne TJ, Pender S, O'Kelly P, et al. Hepatic metastases from an unknown primary neoplasm (UPN): survival, prognostic indicators and value of extensive investigations. Clin Radiol. 2002 Dec;57(12):1073-7.

26. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, et al. Markers of adenocarcinoma characteristic of the site of origin: development of diagnostic algorithm. Clin Cancer Res. 2005;11:3766-72.

27. Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Furuta K, et al. Immunohistochemical Profile for Unknown Primary Adenocarcinoma. PloS ONE. 2012;7:e31181.

28. Stella GM, Senetta R, Cassenti A, Ronco M, Casson P. Cancers of unknown primary origin: current perspectives and future therapeutic strategies. Journal of Translational Medicine. 2012;10:2-11.

29. Park JS, Yim JJ, Kang WJ, Chung JK, Yoo ChG, Kim YW, et al. Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Research Notes. 2011;4:56.

30. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and metaanalysis. EurRadiol. 2009;19:731-44.

31. Boellaard R, Doherty MJ, Weber WA. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: versión 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181-200.

32. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol. 1998;16(6):2105-12.

33. Eickhoff A, Spiethoff A, Hartmann D, Jakobs R, Weickert U, Schilling D, et al. Space-occupying lesions in the liver: incidence of adenocarcinoma metastases of unknown primary site. Dtsch Med Wochenschr. 2007 Feb 23;132(8):369-74.

34. Al-Brahim N, Ross C, Carter B, Chorneyko K. The value of postmortem examination in cases of metastasis of unknown origin-20 year retrospective data from a tertiary care center. Ann Diagnos Pathol. 2005;9:77-80.